Skandinaviska Enskilda Banken AB publ Buys 11,325 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Skandinaviska Enskilda Banken AB publ increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 37.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 41,514 shares of the company’s stock after acquiring an additional 11,325 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in BridgeBio Pharma were worth $1,134,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BBIO. Steward Partners Investment Advisory LLC increased its position in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the period. Advisors Asset Management Inc. grew its stake in shares of BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after acquiring an additional 1,645 shares in the last quarter. Avanza Fonder AB bought a new position in BridgeBio Pharma during the fourth quarter worth about $181,000. First Bank & Trust bought a new stake in BridgeBio Pharma in the 4th quarter valued at about $205,000. Finally, Moss Adams Wealth Advisors LLC acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth approximately $208,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

BBIO has been the subject of a number of analyst reports. Scotiabank lifted their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Bank of America raised their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. Finally, Evercore ISI increased their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.55.

Insider Buying and Selling

In other news, CFO Brian C. Stephenson sold 4,148 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total transaction of $149,991.68. Following the sale, the chief financial officer now directly owns 102,464 shares in the company, valued at approximately $3,705,098.24. The trade was a 3.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $34.90, for a total value of $106,989,998.40. Following the completion of the transaction, the insider now directly owns 22,055,375 shares of the company’s stock, valued at $769,732,587.50. This represents a 12.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,579,739 shares of company stock worth $323,171,901 in the last 90 days. Insiders own 24.66% of the company’s stock.

BridgeBio Pharma Trading Up 0.1 %

Shares of BridgeBio Pharma stock opened at $33.01 on Tuesday. The firm’s 50 day moving average is $33.72 and its 200 day moving average is $28.94. The firm has a market capitalization of $6.28 billion, a PE ratio of -11.58 and a beta of 1.07. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analysts’ expectations of $4.04 million. As a group, research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.